CYP1A2 Antibody (16VII F10F12): sc-73476

CYP1A2 Antibody (16VII F10F12) is a mouse monoclonal IgG1 antibody that detects CYP1A2 in mouse, rat, and human samples through applications such as western blotting (WB) and immunoprecipitation (IP). CYP1A2, also known as Cytochrome P450 1A2, is a crucial heme-thiolate monooxygenase enzyme that plays a significant role in the NADPH-dependent electron transport pathway of liver microsomes. This enzyme is essential for the oxidation of various substrates, including fatty acids, steroids, and xenobiotics, which are vital for drug metabolism and detoxification processes in the liver. Notably, CYP1A2 is involved in the metabolism of several important pharmaceuticals, such as imipramine, propranol, and clozapine, highlighting CYP1A2′s relevance in pharmacokinetics and personalized medicine. CYP1A2 is localized to the membrane of the endoplasmic reticulum, a critical site for metabolic reactions, ensuring efficient substrate processing. Furthermore, CYP1A2 is subject to induction by compounds like 3-methylcholanthrene, insulin, modafinil, and hyperforin, while CYP1A2 activity can be inhibited by various fluoroquinolone antibiotics, caffeine, fluvoxamine, and cimetidine. Importantly, CYP1A2′s involvement in estrogen metabolism has been linked to a reduced risk of breast cancer, underscoring CYP1A2′s potential impact on cancer biology and therapeutic strategies. With broad species reactivity and proven applications, anti-CYP1A2 antibody (16VII F10F12) is an invaluable tool for researchers studying drug metabolism and related health implications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CYP1A2 Antibody (16VII F10F12) References:

1. Functional characterization of 20 allelic variants of CYP1A2.  |  Ito, M., et al. 2015. Drug Metab Pharmacokinet. 30: 247-52. PMID: 26022657
2. CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy.  |  Djordjevic, N., et al. 2016. Eur J Clin Pharmacol. 72: 439-45. PMID: 26762380
3. CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation.  |  Barrangou-Poueys-Darlas, M., et al. 2021. Drug Metab Rev. 53: 30-44. PMID: 33325257
4. ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson's Disease.  |  Siokas, V., et al. 2021. J Clin Med. 10: PMID: 33498513
5. CYP1A2 Genotype Polymorphism Influences the Effect of Caffeine on Anaerobic Performance in Trained Males.  |  Minaei, S., et al. 2022. Int J Sport Nutr Exerc Metab. 32: 16-21. PMID: 34611052
6. Metabolic Activation of Perampanel Mediated by CYP1A2.  |  Ding, Z., et al. 2022. Chem Res Toxicol. 35: 490-498. PMID: 35200000
7. Intermittent Hypoxia Inhibits Hepatic CYP1a2 Expression and Delays Aminophylline Metabolism.  |  Zhang, XB., et al. 2022. Evid Based Complement Alternat Med. 2022: 2782702. PMID: 35529917
8. Circadian oscillator NPAS2 regulates diurnal expression and activity of CYP1A2 in mouse liver.  |  He, Y., et al. 2022. Biochem Pharmacol. 206: 115345. PMID: 36379250
9. Polymorphisms in the gene encoding CYP1A2 influence prostate cancer risk and progression.  |  Vilčková, M., et al. 2023. Oncol Lett. 25: 85. PMID: 36760517
10. Prognostic Value of CYP1A2 (rs2069514 and rs762551) Polymorphisms in COVID-19 Patients.  |  Bozkurt, I., et al. 2023. Balkan J Med Genet. 26: 35-42. PMID: 37576788

The preferred CYP1A1 antibody is CYP1A1 Antibody (B-4): sc-25304.